SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

GSK1482160

Item No. 41980

CAS Registry No.:	1001389-72-5
Formal Name:	(2S)-N-[[2-chloro-3-(trifluoromethyl)phenyl]methyl]-1-methyl-5-oxo-2-pyrrolidinecarboxamide
MF:	$C_{14}H_{14}ClF_3N_2O_2$
FW:	334.7
Purity:	≥95%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK1482160 is supplied as a solid. A stock solution may be made by dissolving the GSK1482160 in the solvent of choice, which should be purged with an inert gas. GSK1482160 is sparingly soluble (1-10 mg/ml) in DMSO and ethanol.

Description

GSK1482160 is an antagonist of the purinergic $P2X_7$ receptor (IC_{50} = 3.2 nM for the human receptor).[1] It inhibits increases in the levels of reactive oxygen species (ROS) induced by LPS and BzATP (Item No. 15577) in THP-1 macrophages when used at a concentration of 1 µM.[2] GSK1482160 (20 mg/kg twice per day) decreases the accumulation of misfolded tau aggregates in the brain and improves learning and memory in the Y-maze and contextual fear conditioning tests in human P301S tau transgenic mice.[3] It reverses mechanical allodynia in a rat model of chronic constriction injury-induced allodynia when administered at a dose of 20 mg/kg.[1]

References

1. Abdi, M.H., Beswick, P.J., Billinton, A., *et al.* Discovery and structure-activity relationships of a series of pyroglutamic acid amide antagonists of the $P2X_7$ receptor. *Bioorg. Med. Chem. Lett.* **20(17),** 5080-5084 (2010).
2. Homerin, G., Jawhara, S., Dezitter, X., *et al.* Pyroglutamide-based P2X7 receptor antagonists targeting inflammatory bowel disease. *J. Med. Chem.* **63(5),** 2074-2094 (2020).
3. Ruan, Z., Delpech, J.-C., Venkatesan Kalavai, S., *et al.* P2RX7 inhibitor suppresses exosome secretion and disease phenotype in P301S tau transgenic mice. *Mol. Neurodegener.* **15(1),** 47 (2020).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM